73 citations
,
September 2016 in “Journal of Translational Medicine” Some heart drugs show promise for other conditions, but more research is needed to confirm their effectiveness and safety.
February 2023 in “Reactions Weekly” September 2003 in “Reactions Weekly” 4 citations
,
April 2019 in “DOAJ (DOAJ: Directory of Open Access Journals)” 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine are the most effective treatments for frontal fibrosing alopecia.
October 2023 in “Journal of Advanced Sciences” Platelet Rich Fibrin (PRF) is a safe, effective tool for tissue regeneration and healing in various medical fields.
30 citations
,
October 2020 in “Nature Communications” Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.
15 citations
,
July 2009 in “Biomedical Chromatography” A reliable method was developed to measure aristolochic acid-I in rat blood.
14 citations
,
June 2011 in “Steroids” New compounds may help treat prostate issues without affecting androgen receptors.
May 2022 in “Reactions Weekly” 19 citations
,
September 2006 in “Journal of Pediatric Gastroenterology and Nutrition” Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.
May 2023 in “Journal of Endocrinology and Reproduction” Blocking cholesterol production may help control hair loss in Primary Cicatricial Alopecia by affecting key regulators.
12 citations
,
December 2012 in “Current Drug Targets” The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
29 citations
,
September 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.
33 citations
,
May 2013 in “Andrologia” Some herbs show promise as antiandrogenic agents.
1 citations
,
March 2016 in “Journal of The American Academy of Dermatology” More research needed to confirm finasteride as standard treatment for FFA.
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
15 citations
,
April 1997 in “Muscle & Nerve” 5 citations
,
April 1997 in “Muscle & Nerve” July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
2 citations
,
January 2014 in “Advanced Biomedical Research” Oral isotretinoin and cyproterone compound are equally effective for treating acne in women with cutaneous hyperandrogenism.
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
13 citations
,
September 2011 in “American Journal of Clinical Dermatology” The oral contraceptive ethinylestradiol/chlormadinone acetate is effective in reducing acne and improving other skin conditions related to high androgen levels.
June 2025 in “Biomolecules” RORA affects hair follicle stem cells' structure and movement, potentially helping treat hair loss.
Newer retinoid drugs are effective for skin conditions but have significant side effects.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
Cepharanthine could be a strong antiviral against COVID-19.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.